These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23074142)

  • 1. Pathway index models for construction of patient-specific risk profiles.
    Eng KH; Wang S; Bradley WH; Rader JS; Kendziorski C
    Stat Med; 2013 Apr; 32(9):1524-35. PubMed ID: 23074142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using knowledge-driven genomic interactions for multi-omics data analysis: metadimensional models for predicting clinical outcomes in ovarian carcinoma.
    Kim D; Li R; Lucas A; Verma SS; Dudek SM; Ritchie MD
    J Am Med Inform Assoc; 2017 May; 24(3):577-587. PubMed ID: 28040685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles.
    Mankoo PK; Shen R; Schultz N; Levine DA; Sander C
    PLoS One; 2011; 6(11):e24709. PubMed ID: 22073136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer.
    Jeong HH; Leem S; Wee K; Sohn KA
    J Ovarian Res; 2015 Jul; 8():42. PubMed ID: 26138921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.
    Wang E; Zaman N; Mcgee S; Milanese JS; Masoudi-Nejad A; O'Connor-McCourt M
    Semin Cancer Biol; 2015 Feb; 30():4-12. PubMed ID: 24747696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ovarian cancer subtype-specific network modules and candidate drivers through an integrative genomics approach.
    Zhang D; Chen P; Zheng CH; Xia J
    Oncotarget; 2016 Jan; 7(4):4298-309. PubMed ID: 26735889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending information retrieval methods to personalized genomic-based studies of disease.
    Ye S; Dawson JA; Kendziorski C
    Cancer Inform; 2014; 13(Suppl 7):85-95. PubMed ID: 25733795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.
    Skirnisdottir I; Mayrhofer M; Rydåker M; Akerud H; Isaksson A
    BMC Cancer; 2012 Sep; 12():407. PubMed ID: 22967087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copy number signatures and mutational processes in ovarian carcinoma.
    Macintyre G; Goranova TE; De Silva D; Ennis D; Piskorz AM; Eldridge M; Sie D; Lewsley LA; Hanif A; Wilson C; Dowson S; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Paul J; Supernat A; Millan D; Hoyle A; Bryson G; Nourse C; Mincarelli L; Sanchez LN; Ylstra B; Jimenez-Linan M; Moore L; Hofmann O; Markowetz F; McNeish IA; Brenton JD
    Nat Genet; 2018 Sep; 50(9):1262-1270. PubMed ID: 30104763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
    Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
    Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
    Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
    Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutual exclusivity analysis identifies oncogenic network modules.
    Ciriello G; Cerami E; Sander C; Schultz N
    Genome Res; 2012 Feb; 22(2):398-406. PubMed ID: 21908773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?
    Tonella L; Giannoccaro M; Alfieri S; Canevari S; De Cecco L
    Curr Treat Options Oncol; 2017 May; 18(5):32. PubMed ID: 28474265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    Narrandes S; Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.
    Zhang T; Xu J; Deng S; Zhou F; Li J; Zhang L; Li L; Wang QE; Li F
    PLoS One; 2018; 13(5):e0196351. PubMed ID: 29723215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach.
    Niculescu AB; Levey DF; Phalen PL; Le-Niculescu H; Dainton HD; Jain N; Belanger E; James A; George S; Weber H; Graham DL; Schweitzer R; Ladd TB; Learman R; Niculescu EM; Vanipenta NP; Khan FN; Mullen J; Shankar G; Cook S; Humbert C; Ballew A; Yard M; Gelbart T; Shekhar A; Schork NJ; Kurian SM; Sandusky GE; Salomon DR
    Mol Psychiatry; 2015 Nov; 20(11):1266-85. PubMed ID: 26283638
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.